{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:58:16Z","timestamp":1794301096966,"version":"4.9.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Top Curr Chem (Z)"],"DOI":"10.1007\/s41061-025-00515-x","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T09:08:23Z","timestamp":1755767303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Total Syntheses of Deuterated Drugs: A Comprehensive Review"],"prefix":"10.1007","volume":"383","author":[{"given":"Ramsha","family":"Munir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer Fawad","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samreen Gul","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Makhdoom","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razia","family":"Noreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Mansha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freeha","family":"Hafeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"515_CR1","first-page":"8","volume":"24","author":"SL Harbeson","year":"2014","unstructured":"Harbeson SL, Tung RD (2014) Deuterium medicinal chemistry: a new approach to drug discovery and development. MedChem News 24:8\u201322","journal-title":"MedChem News"},{"key":"515_CR2","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1021\/jm4007998","volume":"57","author":"TG Gant","year":"2014","unstructured":"Gant TG (2014) Using deuterium in drug discovery: leaving the label in the drug. J Med Chem 57:3595\u20133611","journal-title":"J Med Chem"},{"key":"515_CR3","unstructured":"Ding Y, Zhang L, Cao W (2025) 13.5 insights into the R&D strategies of deuterated drugs from the drug metabolism perspective. In: Drug metabolism and pharmacokinetics: frontiers, strategies, and applications"},{"key":"515_CR4","doi-asserted-by":"publisher","first-page":"19956","DOI":"10.1021\/acsomega.1c02940","volume":"6","author":"T Yamada","year":"2021","unstructured":"Yamada T, Arai K, Kikuchi R, Okamoto S (2021) Deuteration of indole compounds: synthesis of deuterated auxins, indole-3-acetic acid-d5 and indole-3-butyric acid-d5. ACS Omega 6:19956\u201319963","journal-title":"ACS Omega"},{"key":"515_CR5","doi-asserted-by":"crossref","unstructured":"Harbeson SL, Tung RD (2011) Annual reports in medicinal chemistry. Elsevier, pp 403\u2013417","DOI":"10.1016\/B978-0-12-386009-5.00003-5"},{"key":"515_CR6","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.4155\/fmc-2019-0183","volume":"11","author":"S Cargnin","year":"2019","unstructured":"Cargnin S, Serafini M, Pirali T (2019) A primer of deuterium in drug design. Future Med Chem 11:2039\u20132042","journal-title":"Future Med Chem"},{"key":"515_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117371","volume":"287","author":"J Chen","year":"2025","unstructured":"Chen J, Zhu Y-Y, Zhang S-S, Gu S-X (2025) Application of deuterium in research and development of drugs. Eur J Med Chem 287:117371","journal-title":"Eur J Med Chem"},{"key":"515_CR8","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1111\/bph.14454","volume":"175","author":"I Weinsanto","year":"2018","unstructured":"Weinsanto I, Laux-Biehlmann A, Mouheiche J, Maduna T, Delalande F, Chavant V, Gabel F, Darbon P, Charlet A, Poisbeau P (2018) Stable isotope-labelled morphine to study in vivo central and peripheral morphine glucuronidation and brain transport in tolerant mice. Br J Pharmacol 175:3844\u20133856","journal-title":"Br J Pharmacol"},{"key":"515_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/cpdd.241","volume":"5","author":"L Sabounjian","year":"2016","unstructured":"Sabounjian L, Graham P, Wu L, Braman V, Cheng C, Liu J, Shipley J, Neutel J, Dao M (2016) A first-in-patient, multicenter, double-blind, 2-arm, placebo-controlled, randomized safety and tolerability study of a novel oral drug candidate, CTP-499, in chronic kidney disease. Clin Pharmacol Drug Dev 5:314\u2013325","journal-title":"Clin Pharmacol Drug Dev"},{"key":"515_CR10","doi-asserted-by":"publisher","first-page":"10924","DOI":"10.1002\/slct.202002605","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Wang S, Zhang J, Ying H, Zheng H, Dong X, Che J, Chen X, Cheng G (2020) Design, synthesis and pharmacokinetic study of deuterated ticagrelor derivatives. ChemistrySelect 5:10924\u201310927","journal-title":"ChemistrySelect"},{"key":"515_CR11","doi-asserted-by":"crossref","unstructured":"Dean M, Sung VW (2018) Review of deutetrabenazine: a novel treatment for chorea associated with Huntington\u2019s disease. In: Drug design, development and therapy, pp 313\u2013319","DOI":"10.2147\/DDDT.S138828"},{"key":"515_CR12","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s40265-017-0831-0","volume":"77","author":"Y-A Heo","year":"2017","unstructured":"Heo Y-A, Scott LJ (2017) Deutetrabenazine: a review in chorea associated with Huntington\u2019s disease. Drugs 77:1857\u20131864","journal-title":"Drugs"},{"key":"515_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"S Frank","year":"2017","unstructured":"Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, Duker A, Eberly S, Elmer L, Furr-Stimming E (2017) Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol 74:977\u2013982","journal-title":"JAMA Neurol"},{"key":"515_CR14","doi-asserted-by":"crossref","unstructured":"DeWitt SH, Maryanoff BE (2018) vol 57. ACS Publications, pp 472\u2013473","DOI":"10.1021\/acs.biochem.7b00765"},{"key":"515_CR15","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1021\/tx300172s","volume":"25","author":"AM Sharma","year":"2012","unstructured":"Sharma AM, Li Y, Novalen M, Hayes MA, Uetrecht J (2012) Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury. Chem Res Toxicol 25:1708\u20131719","journal-title":"Chem Res Toxicol"},{"key":"515_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0090-9556(24)14935-5","volume":"27","author":"A Mutlib","year":"1999","unstructured":"Mutlib A, Chen H, Nemeth G, Markwalder J, Seitz S, Gan L, Christ D (1999) Identification and characterization of efavirenz metabolites by liquid chromatography\/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 27:1319\u20131333","journal-title":"Drug Metab Dispos"},{"key":"515_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/jlcr.1848","volume":"53","author":"N Modutlwa","year":"2010","unstructured":"Modutlwa N, Maegawa T, Monguchi Y, Sajiki H (2010) Synthesis of deuterium-labelled drugs by hydrogen\u2013deuterium (H\u2013D) exchange using heterogeneous catalysis. J Label Compd Radiopharm 53:686\u2013692","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/acsmedchemlett.0c00052","volume":"11","author":"S DeWitt","year":"2020","unstructured":"DeWitt S, Czarnik AW, Jacques V (2020) Deuterium-enabled chiral switching (DECS) yields chirally pure drugs from chemically interconverting racemates. ACS Med Chem Lett 11:1789\u20131792","journal-title":"ACS Med Chem Lett"},{"key":"515_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1358\/dnp.2010.23.6.1426638","volume":"23","author":"L Shao","year":"2010","unstructured":"Shao L, Hewitt MC (2010) The kinetic isotope effect in the search for deuterated drugs. Drug News Perspect 23:398\u2013404","journal-title":"Drug News Perspect"},{"key":"515_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/cen-10104-buscon1","volume":"101","author":"G Vitale","year":"2023","unstructured":"Vitale G (2023) Deuterium drugs attract investment. CEN Glob Enterp 101:10\u201310","journal-title":"CEN Glob Enterp"},{"key":"515_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11030-015-9655-6","volume":"20","author":"F Li","year":"2016","unstructured":"Li F, Jiang W, Czarnik AW, Li W (2016) Combinatorial synthesis of deuterium-enriched atorvastatin. Mol Divers 20:453\u2013459","journal-title":"Mol Divers"},{"key":"515_CR22","first-page":"12","volume":"2","author":"A Mukharya","year":"2011","unstructured":"Mukharya A, Chaudhary S, Patel N, Mansuri N, Kumar A (2011) Stable and bio-equivalent formulation of HMG-CoA reductase inhibitor: atorvastatin calcium. Int J Pharm Sci Lett 2:12\u201320","journal-title":"Int J Pharm Sci Lett"},{"key":"515_CR23","doi-asserted-by":"publisher","DOI":"10.1201\/9781420028027","volume-title":"Isotope effects in chemistry and biology","author":"A Kohen","year":"2005","unstructured":"Kohen A, Limbach H-H (2005) Isotope effects in chemistry and biology. CRC Press, Boca Raton"},{"key":"515_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/jlcr.3031","volume":"56","author":"FP Guengerich","year":"2013","unstructured":"Guengerich FP (2013) Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions. J Label Compd Radiopharm 56:428\u2013431","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR25","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1021\/acs.jmedchem.8b01808","volume":"62","author":"T Pirali","year":"2019","unstructured":"Pirali T, Serafini M, Cargnin S, Genazzani AA (2019) Applications of deuterium in medicinal chemistry. J Med Chem 62:5276\u20135297","journal-title":"J Med Chem"},{"key":"515_CR26","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/anie.201704146","volume":"57","author":"J Atzrodt","year":"2018","unstructured":"Atzrodt J, Derdau V, Kerr WJ, Reid M (2018) Deuterium-and tritium-labelled compounds: applications in the life sciences. Angew Chem Int Ed 57:1758\u20131784","journal-title":"Angew Chem Int Ed"},{"key":"515_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400836","volume":"20","author":"Y Chen","year":"2025","unstructured":"Chen Y, Du Y (2025) The application of deuteration strategy in drug design. ChemMedChem 20:e202400836","journal-title":"ChemMedChem"},{"key":"515_CR28","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1039\/D0CS01496F","volume":"51","author":"G Prakash","year":"2022","unstructured":"Prakash G, Paul N, Oliver GA, Werz DB, Maiti D (2022) C\u2013H deuteration of organic compounds and potential drug candidates. Chem Soc Rev 51:3123\u20133163","journal-title":"Chem Soc Rev"},{"key":"515_CR29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/cjoc.202300570","volume":"42","author":"H Li","year":"2024","unstructured":"Li H, Shabbir M, Li W, Lei A (2024) Recent advances in deuteration reactions. Chin J Chem 42:1145\u20131156","journal-title":"Chin J Chem"},{"key":"515_CR30","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/s41467-020-15310-z","volume":"11","author":"J Rowbotham","year":"2020","unstructured":"Rowbotham J, Ramirez MA, Lenz O, Reeve H, Vincent K (2020) Bringing biocatalytic deuteration into the toolbox of asymmetric isotopic labelling techniques. Nat Commun 11:1454","journal-title":"Nat Commun"},{"key":"515_CR31","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1016\/j.tetlet.2014.04.025","volume":"55","author":"CS Donald","year":"2014","unstructured":"Donald CS, Moss TA, Noonan GM, Roberts B, Durham EC (2014) Deuterodehalogenation\u2014A mild method for synthesising deuterated heterocycles. Tetrahedron Lett 55:3305\u20133307","journal-title":"Tetrahedron Lett"},{"key":"515_CR32","doi-asserted-by":"publisher","first-page":"7744","DOI":"10.1002\/anie.200700039","volume":"46","author":"J Atzrodt","year":"2007","unstructured":"Atzrodt J, Derdau V, Fey T, Zimmermann J (2007) The renaissance of H\/D exchange. Angew Chem Int Ed 46:7744\u20137765","journal-title":"Angew Chem Int Ed"},{"key":"515_CR33","doi-asserted-by":"publisher","first-page":"3502872","DOI":"10.1155\/2022\/3502872","volume":"2022","author":"I Shahzadi","year":"2022","unstructured":"Shahzadi I, Zahoor AF, Parveen B, Rasul A, Raza Z, Ahmad S, Irfan A, El-Hiti GA (2022) Acefylline derivatives as a new class of anticancer agents: synthesis, molecular docking, and anticancer, hemolytic, and thrombolytic activities of acefylline-triazole hybrids. J Chem 2022:3502872","journal-title":"J Chem"},{"key":"515_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nature04077","volume":"436","author":"BD Lindenbach","year":"2005","unstructured":"Lindenbach BD, Rice CM (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436:933\u2013938","journal-title":"Nature"},{"key":"515_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1053\/jhep.2002.30531","volume":"35","author":"AM Di Bisceglie","year":"2002","unstructured":"Di Bisceglie AM, McHutchison J, Rice CM (2002) New therapeutic strategies for hepatitis C. Hepatology 35:224\u2013231","journal-title":"Hepatology"},{"key":"515_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/jlcr.1905","volume":"54","author":"AJ Morgan","year":"2011","unstructured":"Morgan AJ, Nguyen S, Uttamsingh V, Bridson G, Harbeson S, Tung R, Masse CE (2011) Design and synthesis of deuterated boceprevir analogs with enhanced pharmacokinetic properties. J Label Compd Radiopharm 54:613\u2013624","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","volume":"131","author":"HW Reesink","year":"2006","unstructured":"Reesink HW, Zeuzem S, Weegink CJ, Forestier N, Van Vliet A, de Rooij JW, McNair L, Purdy S, Kauffman R, Alam J (2006) Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997\u20131002","journal-title":"Gastroenterology"},{"key":"515_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jhep.2008.03.027","volume":"49","author":"E Lawitz","year":"2008","unstructured":"Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG (2008) Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 49:163\u2013169","journal-title":"J Hepatol"},{"key":"515_CR39","doi-asserted-by":"publisher","first-page":"7993","DOI":"10.1021\/jm901023f","volume":"52","author":"F Maltais","year":"2009","unstructured":"Maltais F, Jung YC, Chen M, Tanoury J, Perni RB, Mani N, Laitinen L, Huang H, Liao S, Gao H (2009) In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem 52:7993\u20138001","journal-title":"J Med Chem"},{"key":"515_CR40","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543776.16.8.1067","volume":"16","author":"A Mastrolorenzo","year":"2006","unstructured":"Mastrolorenzo A, Rusconi S, Scozzafava A, Supuran CT (2006) Inhibitors of HIV-1 protease: 10 years after. Expert Opin Ther Pat 16:1067\u20131091","journal-title":"Expert Opin Ther Pat"},{"key":"515_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/jac\/dkm122","volume":"60","author":"JP Lalezari","year":"2007","unstructured":"Lalezari JP, Ward DJ, Tomkins SA, Garges HP (2007) Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006. J Antimicrob Chemother 60:170\u2013174","journal-title":"J Antimicrob Chemother"},{"key":"515_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejmech.2013.02.001","volume":"63","author":"EJ Velthuisen","year":"2013","unstructured":"Velthuisen EJ, Baughman TM, Johns BA, Temelkoff DP, Weatherhead JG (2013) Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs. Eur J Med Chem 63:202\u2013212","journal-title":"Eur J Med Chem"},{"key":"515_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s11030-016-9686-7","volume":"20","author":"S Faiz","year":"2016","unstructured":"Faiz S, Zahoor AF (2016) Ring opening of epoxides with C-nucleophiles. Mol Divers 20:969\u2013987","journal-title":"Mol Divers"},{"key":"515_CR44","doi-asserted-by":"publisher","first-page":"12708","DOI":"10.3390\/ijms252312708","volume":"25","author":"AF Zahoor","year":"2024","unstructured":"Zahoor AF, Munawar S, Ahmad S, Iram F, Anjum MN, Khan SG, Javid J, Nazeer U, Bhat MA (2024) Design, synthesis and biological exploration of novel N-(9-ethyl-9 H-carbazol-3-yl) acetamide-linked benzofuran-1, 2, 4-triazoles as anti-SARS-CoV-2 agents: combined wet\/dry approach targeting main protease (Mpro), spike glycoprotein and RdRp. Int J Mol Sci 25:12708","journal-title":"Int J Mol Sci"},{"key":"515_CR45","doi-asserted-by":"publisher","first-page":"11414","DOI":"10.1021\/acs.joc.4c01089","volume":"89","author":"F-Y Zhu","year":"2024","unstructured":"Zhu F-Y, Wu B-D, Du M-H, Yao J-L, Abrahams BF, Gu H, Braunstein P, Lang J-P (2024) Tandem protocol for diversified deuteration of secondary aliphatic amines under mild conditions. J Org Chem 89:11414\u201311420","journal-title":"J Org Chem"},{"key":"515_CR46","doi-asserted-by":"publisher","first-page":"18577","DOI":"10.1039\/D5RA02615F","volume":"15","author":"R Kausar","year":"2025","unstructured":"Kausar R, Mansha A, Zahoor AF, Haroon M (2025) Synthesis and anti-SARS-CoV-2 potential of novel coumarin hybrids: a combined wet\/dry lab approach targeting M Pro, Nsp15 and spike protein. RSC Adv 15:18577\u201318592","journal-title":"RSC Adv"},{"key":"515_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105586","volume":"213","author":"Y Yang","year":"2023","unstructured":"Yang Y, Cao L, Yan M, Zhou J, Yang S, Xu T, Huang S, Li K, Zhou Q, Li G (2023) Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2. Antivir Res 213:105586","journal-title":"Antivir Res"},{"key":"515_CR48","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/molecules27031023","volume":"27","author":"A Irfan","year":"2022","unstructured":"Irfan A, Faiz S, Rasul A, Zafar R, Zahoor AF, Kotwica-Mojzych K, Mojzych M (2022) Exploring the synergistic anticancer potential of benzofuran\u2013oxadiazoles and triazoles: improved ultrasound-and microwave-assisted synthesis, molecular docking, hemolytic, thrombolytic and anticancer evaluation of furan-based molecules. Molecules 27:1023","journal-title":"Molecules"},{"key":"515_CR49","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1200\/JCO.2009.25.4029","volume":"28","author":"EB Haura","year":"2010","unstructured":"Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A (2010) Phase I\/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non\u2013small-cell lung cancer. J Clin Oncol 28:1387\u20131394","journal-title":"J Clin Oncol"},{"key":"515_CR50","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/ijc.27504","volume":"131","author":"C Ling","year":"2012","unstructured":"Ling C, Chen G, Chen G, Zhang Z, Cao B, Han K, Yin J, Chu A, Zhao Y, Mao X (2012) A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo. Int J Cancer 131:2411\u20132419","journal-title":"Int J Cancer"},{"key":"515_CR51","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","volume":"67","author":"HY Zou","year":"2007","unstructured":"Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung P-P (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408\u20134417","journal-title":"Cancer Res"},{"key":"515_CR52","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui JJ, Tran-Dub\u00e9 M, Shen H, Nambu M, Kung P-P, Pairish M, Jia L, Meng J, Funk L, Botrous I (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal\u2013epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54:6342\u20136363","journal-title":"J Med Chem"},{"key":"515_CR53","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/jlcr.3678","volume":"61","author":"W Ao","year":"2018","unstructured":"Ao W, Li Y, Zhang Y (2018) Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Label Compd Radiopharm 61:1036\u20131042","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR54","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1021\/jm2009088","volume":"55","author":"Y Yamazaki","year":"2012","unstructured":"Yamazaki Y, Tanaka K, Nicholson B, Deyanat-Yazdi G, Potts B, Yoshida T, Oda A, Kitagawa T, Orikasa S, Kiso Y (2012) Synthesis and structure\u2013activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2, 5-dione structure. J Med Chem 55:1056\u20131071","journal-title":"J Med Chem"},{"key":"515_CR55","first-page":"5692","volume":"117","author":"AV Singh","year":"2011","unstructured":"Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC (2011) A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood J Am Soc Hematol 117:5692\u20135700","journal-title":"Blood J Am Soc Hematol"},{"key":"515_CR56","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.bmcl.2017.01.096","volume":"27","author":"Z Ding","year":"2017","unstructured":"Ding Z, Cheng H, Wang S, Hou Y, Zhao J, Guan H, Li W (2017) Development of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent. Bioorg Med Chem Lett 27:1416\u20131419","journal-title":"Bioorg Med Chem Lett"},{"key":"515_CR57","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc796","volume":"2","author":"A Ruiz I Altaba","year":"2002","unstructured":"Ruiz I Altaba A, Sanchez P, Dahmane N (2002) Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2:361\u2013372","journal-title":"Nat Rev Cancer"},{"key":"515_CR58","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1634\/theoncologist.2011-0450","volume":"17","author":"S Sahebjam","year":"2012","unstructured":"Sahebjam S, Siu LL, Razak AA (2012) The utility of hedgehog signaling pathway inhibition for cancer. Oncologist 17:1090\u20131099","journal-title":"Oncologist"},{"key":"515_CR59","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.coph.2012.07.002","volume":"12","author":"NA Riobo","year":"2012","unstructured":"Riobo NA (2012) Cholesterol and its derivatives in Sonic Hedgehog signaling and cancer. Curr Opin Pharmacol 12:736\u2013741","journal-title":"Curr Opin Pharmacol"},{"key":"515_CR60","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-0975","volume":"17","author":"H Wong","year":"2011","unstructured":"Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, Gould SE (2011) Pharmacokinetic\u2013pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res 17:4682\u20134692","journal-title":"Clin Cancer Res"},{"key":"515_CR61","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.bmcl.2018.06.025","volume":"28","author":"F Wang","year":"2018","unstructured":"Wang F, Jiang H, Deng Y, Yu J, Zhan M, Zhao L, Chen Y (2018) Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties. Bioorg Med Chem Lett 28:2399\u20132402","journal-title":"Bioorg Med Chem Lett"},{"key":"515_CR62","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/gutjnl-2013-306627","volume":"63","author":"J Bruix","year":"2014","unstructured":"Bruix J, Gores GJ, Mazzaferro V (2014) Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63:844\u2013855","journal-title":"Gut"},{"key":"515_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","volume":"69","author":"GM Keating","year":"2009","unstructured":"Keating GM, Santoro A (2009) Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69:223\u2013240","journal-title":"Drugs"},{"key":"515_CR64","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s40265-021-01603-0","volume":"81","author":"SJ Keam","year":"2021","unstructured":"Keam SJ, Duggan S (2021) Donafenib: first approval. Drugs 81:1915\u20131920","journal-title":"Drugs"},{"key":"515_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11030-018-9875-7","volume":"23","author":"L Zhong","year":"2019","unstructured":"Zhong L, Hou C, Zhang L, Zhao J, Li F, Li W (2019) Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Mol Divers 23:341\u2013350","journal-title":"Mol Divers"},{"key":"515_CR66","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2011.01.010","volume":"302","author":"H-J Nam","year":"2011","unstructured":"Nam H-J, Kim H-P, Yoon Y-K, Hur H-S, Song S-H, Kim M-S, Lee G-S, Han S-W, Im S-A, Kim T-Y (2011) Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 302:155\u2013165","journal-title":"Cancer Lett"},{"key":"515_CR67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00280-014-2621-7","volume":"75","author":"Y-H Noh","year":"2015","unstructured":"Noh Y-H, Lim H-S, Jung J-A, Song TH, Bae K-S (2015) Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies. Cancer Chemother Pharmacol 75:97\u2013109","journal-title":"Cancer Chemother Pharmacol"},{"key":"515_CR68","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1248\/bpb.b19-00153","volume":"42","author":"S Ma","year":"2019","unstructured":"Ma S, Wang L, Ouyang B, Bai X, Ji Q, Yao L (2019) The design, synthesis and preliminary pharmacokinetic evaluation of d3-poziotinib hydrochloride. Biol Pharm Bull 42:873\u2013876","journal-title":"Biol Pharm Bull"},{"key":"515_CR69","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"515_CR70","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72:1494\u20131503","journal-title":"Cancer Res"},{"key":"515_CR71","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.bmcl.2017.04.071","volume":"27","author":"X Pang","year":"2017","unstructured":"Pang X, Wang Y, Chen Y (2017) Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles. Bioorg Med Chem Lett 27:2803\u20132806","journal-title":"Bioorg Med Chem Lett"},{"key":"515_CR72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mnfr.200700511","volume":"53","author":"PD Baade","year":"2009","unstructured":"Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53:171\u2013184","journal-title":"Mol Nutr Food Res"},{"key":"515_CR73","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1021\/jm901488g","volume":"53","author":"ME Jung","year":"2010","unstructured":"Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J (2010) Structure\u2013activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 53:2779\u20132796","journal-title":"J Med Chem"},{"key":"515_CR74","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jlcr.3516","volume":"60","author":"X Pang","year":"2017","unstructured":"Pang X, Peng L, Chen Y (2017) Effect of N-methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide. J Label Compd Radiopharm 60:401\u2013409","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR75","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1021\/jm501562a","volume":"58","author":"GJ Roth","year":"2015","unstructured":"Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin S-L, Kaiser R (2015) Nintedanib: from discovery to the clinic. J Med Chem 58:1053\u20131063","journal-title":"J Med Chem"},{"key":"515_CR76","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071\u20132082","journal-title":"N Engl J Med"},{"key":"515_CR77","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/jlcr.3299","volume":"58","author":"R Xu","year":"2015","unstructured":"Xu R, Zhan M, Peng L, Pang X, Yang J, Zhang T, Jiang H, Zhao L, Chen Y (2015) Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties. J Label Compd Radiopharm 58:308\u2013312","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR78","doi-asserted-by":"publisher","first-page":"9134","DOI":"10.1158\/0008-5472.CAN-05-4290","volume":"66","author":"K Nakamura","year":"2006","unstructured":"Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y (2006) KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 66:9134\u20139142","journal-title":"Cancer Res"},{"key":"515_CR79","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1349-7006.2007.00724.x","volume":"99","author":"E Taguchi","year":"2008","unstructured":"Taguchi E, Nakamura K, Miura T, Shibuya M, Isoe T (2008) Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci 99:623\u2013630","journal-title":"Cancer Sci"},{"key":"515_CR80","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.bmcl.2015.03.088","volume":"25","author":"S Guo","year":"2015","unstructured":"Guo S, Pang X, Peng L, Zhan M, Fan L, Gong Y, Kang F, Chen Y (2015) Design, synthesis and biological evaluation of deuterated tivozanib for improving pharmacokinetic properties. Bioorg Med Chem Lett 25:2425\u20132428","journal-title":"Bioorg Med Chem Lett"},{"key":"515_CR81","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1592\/phco.30.9.904","volume":"30","author":"OO Oyetayo","year":"2010","unstructured":"Oyetayo OO, Rogers CE, Hofmann PO (2010) Dronedarone: a new antiarrhythmic agent. Pharmacother J Hum Pharmacol Drug Ther 30:904\u2013915","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"515_CR82","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/jlcr.3090","volume":"56","author":"J Schofield","year":"2013","unstructured":"Schofield J, Brasseur D, de Bruin B, Vassal T, Klieber S, Arabeyre C, Bourri\u00e9 M, Sadoun F, Fabre G (2013) Effect of deuteration on the metabolism and clearance of some pharmacologically active compounds\u2014Synthesis and in vitro metabolism of deuterated derivatives of dronedadrone. J Label Compd Radiopharm 56:504\u2013512","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR83","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.31083\/j.rcm2204143","volume":"22","author":"L Pannone","year":"2021","unstructured":"Pannone L, D\u2019Angelo G, Gulletta S, Falasconi G, Brugliera L, Frontera A, Cianfanelli L, Baldetti L, Ossola P, Melillo F (2021) Amiodarone in ventricular arrhythmias: still a valuable resource? Rev Cardiovasc Med 22:1383\u20131392","journal-title":"Rev Cardiovasc Med"},{"key":"515_CR84","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/01.md.0000123095.65294.34","volume":"83","author":"D Kurnik","year":"2004","unstructured":"Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D (2004) Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine 83:107\u2013113","journal-title":"Medicine"},{"key":"515_CR85","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/clpt.2011.283","volume":"91","author":"M McDonald","year":"2012","unstructured":"McDonald M, Au N, Wittkowsky A, Rettie A (2012) Warfarin\u2013amiodarone drug\u2013drug interactions: determination of [I] u\/KI, u for amiodarone and its plasma metabolites. Clin Pharmacol Ther 91:709\u2013717","journal-title":"Clin Pharmacol Ther"},{"key":"515_CR86","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2174\/157340607782360353","volume":"3","author":"AB Reitz","year":"2007","unstructured":"Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR (2007) The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem 3:543\u2013545","journal-title":"Med Chem"},{"key":"515_CR87","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11030-016-9660-4","volume":"20","author":"F Li","year":"2016","unstructured":"Li F, Jiang W, Czarnik AW, Li W (2016) Combinatorial synthesis of deuterium-enriched (S)-oxybutynin. Mol Divers 20:605\u2013610","journal-title":"Mol Divers"},{"key":"515_CR88","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1007\/s11696-022-02424-5","volume":"76","author":"R Akhtar","year":"2022","unstructured":"Akhtar R, Zahoor AF, Irfan M, Bokhari TH, ul Haq A (2022) Recent green synthetic approaches toward Ullmann reaction: a review. Chem Pap 76:7275\u20137293","journal-title":"Chem Pap"},{"key":"515_CR89","doi-asserted-by":"crossref","unstructured":"Birks JS, Evans JG (2015) Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD001191.pub3"},{"key":"515_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000923","volume":"4","author":"E Torreele","year":"2010","unstructured":"Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazu\u00e9 G, Bray MA, P\u00e9coul B (2010) Fexinidazole \u2013 A new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4:e923","journal-title":"PLoS Negl Trop Dis"},{"key":"515_CR91","doi-asserted-by":"publisher","first-page":"10638","DOI":"10.1002\/ange.201905870","volume":"131","author":"M Xiao","year":"2019","unstructured":"Xiao M, Yue X, Xu R, Tang W, Xue D, Li C, Lei M, Xiao J, Wang C (2019) Transition-metal-free hydrogen autotransfer: diastereoselective N-alkylation of amines with racemic alcohols. Angew Chem 131:10638\u201310646","journal-title":"Angew Chem"},{"key":"515_CR92","doi-asserted-by":"publisher","first-page":"10979","DOI":"10.3390\/ijms231810979","volume":"23","author":"A Irfan","year":"2022","unstructured":"Irfan A, Zahoor AF, Kamal S, Hassan M, Kloczkowski A (2022) Ultrasonic-assisted synthesis of benzofuran appended oxadiazole molecules as tyrosinase inhibitors: mechanistic approach through enzyme inhibition, molecular docking, chemoinformatics, ADMET and drug-likeness studies. Int J Mol Sci 23:10979","journal-title":"Int J Mol Sci"},{"key":"515_CR93","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/ph16060829","volume":"16","author":"A Irfan","year":"2023","unstructured":"Irfan A, Faisal S, Zahoor AF, Noreen R, Al-Hussain SA, Tuzun B, Javaid R, Elhenawy AA, Zaki ME, Ahmad S (2023) In silico development of novel benzofuran-1, 3, 4-oxadiazoles as lead inhibitors of M. tuberculosis polyketide synthase 13. Pharmaceuticals 16:829","journal-title":"Pharmaceuticals"},{"key":"515_CR94","doi-asserted-by":"publisher","first-page":"1403168","DOI":"10.3389\/fmicb.2024.1403168","volume":"15","author":"S Sharma","year":"2024","unstructured":"Sharma S, Chauhan A, Ranjan A, Mathkor DM, Haque S, Ramniwas S, Tuli HS, Jindal T, Yadav V (2024) Emerging challenges in antimicrobial resistance: implications for pathogenic microorganisms, novel antibiotics, and their impact on sustainability. Front Microbiol 15:1403168","journal-title":"Front Microbiol"},{"key":"515_CR95","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/ph16030344","volume":"16","author":"A Irfan","year":"2023","unstructured":"Irfan A, Faisal S, Ahmad S, Al-Hussain SA, Javed S, Zahoor AF, Parveen B, Zaki ME (2023) Structure-based virtual screening of furan-1, 3, 4-oxadiazole tethered N-phenylacetamide derivatives as novel class of hTYR and hTYRP1 inhibitors. Pharmaceuticals 16:344","journal-title":"Pharmaceuticals"},{"key":"515_CR96","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","volume":"375","author":"R Brun","year":"2010","unstructured":"Brun R, Blum J, Chappuis F, Burri C (2010) Human African trypanosomiasis. Lancet 375:148\u2013159","journal-title":"Lancet"},{"key":"515_CR97","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jlcr.1914","volume":"54","author":"E Fontana","year":"2011","unstructured":"Fontana E, Pignatti A, Venegoni S, Bray MA (2011) Synthesis of 2H-and 14C-labeled fexinidazole and its primary metabolites labeled with 2H. J Label Compd Radiopharm 54:714\u2013719","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR98","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104\u2013112","journal-title":"J Am Soc Nephrol"},{"key":"515_CR99","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/jm701272q","volume":"51","author":"W Meng","year":"2008","unstructured":"Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA (2008) Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51:1145\u20131149","journal-title":"J Med Chem"},{"key":"515_CR100","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/jm401780b","volume":"57","author":"G Xu","year":"2014","unstructured":"Xu G, Lv B, Roberge JY, Xu B, Du J, Dong J, Chen Y, Peng K, Zhang L, Tang X (2014) Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes. J Med Chem 57:1236\u20131251","journal-title":"J Med Chem"},{"key":"515_CR101","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1021\/jm101405t","volume":"54","author":"S Sasaki","year":"2011","unstructured":"Sasaki S, Kitamura S, Negoro N, Suzuki M, Tsujihata Y, Suzuki N, Santou T, Kanzaki N, Harada M, Tanaka Y (2011) Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. J Med Chem 54:1365\u20131378","journal-title":"J Med Chem"},{"key":"515_CR102","unstructured":"Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA (2016) ACS Publications"},{"key":"515_CR103","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.bmcl.2019.04.019","volume":"29","author":"B Liu","year":"2019","unstructured":"Liu B, Deng L, Chen H, Liao R, Li Y, Zeng X, Deng F, Zhang L, Li Z (2019) Design, synthesis and biological activity of deuterium-based FFA1 agonists with improved pharmacokinetic profiles. Bioorg Med Chem Lett 29:1471\u20131475","journal-title":"Bioorg Med Chem Lett"},{"key":"515_CR104","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, Ritchie D, Stewart A, Neeson P, Harrison S, Smyth M, Prince H (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24:22\u201332","journal-title":"Leukemia"},{"key":"515_CR105","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1358\/dof.2004.029.04.792298","volume":"29","author":"Y Hashimoto","year":"2004","unstructured":"Hashimoto Y, Tanatani A, Nagasawa K, Miyachi H (2004) Thalidomide as a multi-target drug and its application as a template for drug design. Drugs Future 29:383\u2013391","journal-title":"Drugs Future"},{"key":"515_CR106","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3816\/CGC.2004.n.014","volume":"3","author":"WN Brennen","year":"2004","unstructured":"Brennen WN, Cooper CR, Capitosti S, Brown ML, Sikes RA (2004) Thalidomide and analogues: current proposed mechanisms and therapeutic usage. Clin Prostate Cancer 3:54\u201361","journal-title":"Clin Prostate Cancer"},{"key":"515_CR107","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1021\/ol401705a","volume":"15","author":"JA Burkhard","year":"2013","unstructured":"Burkhard JA, Wuitschik G, Plancher J-M, Rogers-Evans M, Carreira EM (2013) Synthesis and stability of oxetane analogs of thalidomide and lenalidomide. Org Lett 15:4312\u20134315","journal-title":"Org Lett"},{"key":"515_CR108","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1248\/cpb.58.110","volume":"58","author":"T Yamamoto","year":"2010","unstructured":"Yamamoto T, Tokunaga E, Nakamura S, Shibata N, Toru T (2010) Synthesis and configurational stability of (S)-and (R)-deuteriothalidomides. Chem Pharm Bull 58:110\u2013112","journal-title":"Chem Pharm Bull"},{"key":"515_CR109","doi-asserted-by":"publisher","first-page":"E1471","DOI":"10.1073\/pnas.1417832112","volume":"112","author":"V Jacques","year":"2015","unstructured":"Jacques V, Czarnik AW, Judge TM, Van der Ploeg LH, DeWitt SH (2015) Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs. Proc Natl Acad Sci USA 112:E1471\u2013E1479","journal-title":"Proc Natl Acad Sci USA"},{"key":"515_CR110","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-015-0350-9","volume":"75","author":"ES Kim","year":"2015","unstructured":"Kim ES, Keating GM (2015) Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs 75:219\u2013230","journal-title":"Drugs"},{"key":"515_CR111","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760\u20131769","journal-title":"Lancet"},{"key":"515_CR112","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","volume":"62","author":"SM Ruwanpura","year":"2020","unstructured":"Ruwanpura SM, Thomas BJ, Bardin PG (2020) Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol 62:413\u2013422","journal-title":"Am J Respir Cell Mol Biol"},{"key":"515_CR113","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821\u2013829","journal-title":"Eur Respir J"},{"key":"515_CR114","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1039\/C7GC01740E","volume":"19","author":"E Falb","year":"2017","unstructured":"Falb E, Ulanenko K, Tor A, Gottesfeld R, Weitman M, Afri M, Gottlieb H, Hassner A (2017) A highly efficient Suzuki\u2013Miyaura methylation of pyridines leading to the drug pirfenidone and its CD 3 version (SD-560). Green Chem 19:5046\u20135053","journal-title":"Green Chem"},{"key":"515_CR115","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.saa.2018.06.016","volume":"204","author":"Q Yin","year":"2018","unstructured":"Yin Q, Chen Y, Zhou M, Jiang X, Wu J, Sun Y (2018) Synthesis and photophysical properties of deuteration of pirfenidone. Spectrochim Acta Part A Mol Biomol Spectrosc 204:88\u201398","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"},{"key":"515_CR116","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1126\/science.1099736","volume":"305","author":"PA Williams","year":"2004","unstructured":"Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683\u2013686","journal-title":"Science"},{"key":"515_CR117","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/jlcr.1451","volume":"50","author":"PM Gannett","year":"2007","unstructured":"Gannett PM, Miller L, Daft J, Locuson C, Tracy TS (2007) Synthesis of deuterated naproxens. J Label Compd Radiopharm 50:1272\u20131275","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR118","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cmtd.202100016","volume":"1","author":"T Rajbongshi","year":"2021","unstructured":"Rajbongshi T, Kumar Sarmah K, Ganduri R, Cherukuvada S, Arhangelskis M, Thakuria R (2021) Mechanosynthesis of eutectics of anti-inflammatory drug ethenzamide\u2014A comparison with analogous cocrystals. Chem Methods 1:408\u2013414","journal-title":"Chem Methods"},{"key":"515_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202311058","volume":"62","author":"K Ban","year":"2023","unstructured":"Ban K, Imai K, Oyama S, Tokunaga J, Ikeda Y, Uchiyama H, Kadota K, Tozuka Y, Akai S, Sawama Y (2023) Sulfonium salt reagents for the introduction of deuterated alkyl groups in drug discovery. Angew Chem Int Ed 62:e202311058","journal-title":"Angew Chem Int Ed"},{"key":"515_CR120","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00737-007-0209-5","volume":"10","author":"D Deecher","year":"2007","unstructured":"Deecher D, Dorries K (2007) Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 10:247\u2013257","journal-title":"Arch Womens Ment Health"},{"key":"515_CR121","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/ijms22041662","volume":"22","author":"M Kowalska","year":"2021","unstructured":"Kowalska M, Nowaczyk J, Fija\u0142kowski \u0141, Nowaczyk A (2021) Paroxetine\u2014Overview of the molecular mechanisms of action. Int J Mol Sci 22:1662","journal-title":"Int J Mol Sci"},{"key":"515_CR122","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1124\/jpet.115.223768","volume":"354","author":"V Uttamsingh","year":"2015","unstructured":"Uttamsingh V, Gallegos R, Liu JF, Harbeson SL, Bridson GW, Cheng C, Wells DS, Graham PB, Zelle R, Tung R (2015) Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine. J Pharmacol Exp Ther 354:43\u201354","journal-title":"J Pharmacol Exp Ther"},{"key":"515_CR123","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3109\/00498258409151492","volume":"14","author":"B Kaye","year":"1984","unstructured":"Kaye B, Offerman J, Reid J, Elliott H, Hillis W (1984) A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 14:935\u2013945","journal-title":"Xenobiotica"},{"key":"515_CR124","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1124\/dmd.109.030783","volume":"38","author":"D Dalvie","year":"2010","unstructured":"Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, Loi C-M (2010) Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 38:641\u2013654","journal-title":"Drug Metab Dispos"},{"key":"515_CR125","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1124\/dmd.111.042770","volume":"40","author":"R Sharma","year":"2012","unstructured":"Sharma R, Strelevitz TJ, Gao H, Clark AJ, Schildknegt K, Obach RS, Ripp SL, Spracklin DK, Tremaine LM, Vaz AD (2012) Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs. Drug Metab Dispos 40:625\u2013634","journal-title":"Drug Metab Dispos"},{"key":"515_CR126","first-page":"174","volume-title":"Seminars in thrombosis and hemostasis","author":"P Savi","year":"2005","unstructured":"Savi P, Herbert J-M (2005) Seminars in thrombosis and hemostasis, vol 31. Thieme Medical Publishers Inc, New York, pp 174\u2013183"},{"key":"515_CR127","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1021\/tx8004828","volume":"22","author":"PM Dansette","year":"2009","unstructured":"Dansette PM, Libraire J, Bertho G, Mansuy D (2009) Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem Res Toxicol 22:369\u2013373","journal-title":"Chem Res Toxicol"},{"key":"515_CR128","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1021\/ml300460t","volume":"4","author":"Y Zhu","year":"2013","unstructured":"Zhu Y, Zhou J, Jiao B (2013) Deuterated clopidogrel analogues as a new generation of antiplatelet agents. ACS Med Chem Lett 4:349\u2013352","journal-title":"ACS Med Chem Lett"},{"key":"515_CR129","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/molecules21060704","volume":"21","author":"X Xu","year":"2016","unstructured":"Xu X, Zhao X, Yang Z, Wang H, Meng X, Su C, Liu M, Fawcett JP, Yang Y, Gu J (2016) Significant improvement of metabolic characteristics and bioactivities of clopidogrel and analogs by selective deuteration. Molecules 21:704","journal-title":"Molecules"},{"key":"515_CR130","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1016\/j.bmcl.2007.07.057","volume":"17","author":"B Springthorpe","year":"2007","unstructured":"Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG (2007) From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 17:6013\u20136018","journal-title":"Bioorg Med Chem Lett"},{"key":"515_CR131","doi-asserted-by":"crossref","unstructured":"Munawar S, Zahoor AF, Hussain SM, Ahmad S, Mansha A, Parveen B, Ali KG, Irfan A (2024) Steglich esterification: a versatile synthetic approach toward the synthesis of natural products, their analogues\/derivatives. Heliyon 10","DOI":"10.1016\/j.heliyon.2023.e23416"},{"key":"515_CR132","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.2146\/ajhp100348","volume":"68","author":"ML Blommel","year":"2011","unstructured":"Blommel ML, Blommel AL (2011) Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm 68:1506\u20131519","journal-title":"Am J Health Syst Pharm"},{"key":"515_CR133","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/eurheartj\/ehm575","volume":"29","author":"AG Turpie","year":"2008","unstructured":"Turpie AG (2008) New oral anticoagulants in atrial fibrillation. Eur Heart J 29:155\u2013165","journal-title":"Eur Heart J"},{"key":"515_CR134","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1007\/s10967-024-09584-6","volume":"333","author":"M He","year":"2024","unstructured":"He M, Li J, Sun W, Tian L (2024) Synthesis of deuterium labeled dabigatran etexilate. J Radioanal Nucl Chem 333:5391\u20135397","journal-title":"J Radioanal Nucl Chem"},{"key":"515_CR135","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0091270010375957","volume":"51","author":"SS Gottlieb","year":"2011","unstructured":"Gottlieb SS, Ticho B, Deykin A, Abraham WT, DeNofrio D, Russell SD, Chapman D, Smith W, Goldman S, Thomas I (2011) Effects of BG9928, an adenosine A1 receptor antagonist, in patients with congestive heart failure. J Clin Pharmacol 51:899\u2013907","journal-title":"J Clin Pharmacol"},{"key":"515_CR136","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1021\/jm0605381","volume":"49","author":"WF Kiesman","year":"2006","unstructured":"Kiesman WF, Zhao J, Conlon PR, Dowling JE, Petter RC, Lutterodt F, Jin X, Smits G, Fure M, Jayaraj A (2006) Potent and orally bioavailable 8-bicyclo [2.2. 2] octylxanthines as adenosine A1 receptor antagonists. J Med Chem 49:7119\u20137131","journal-title":"J Med Chem"},{"key":"515_CR137","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jlcr.1237","volume":"50","author":"PR Conlon","year":"2007","unstructured":"Conlon PR, Kiesman WF (2007) Synthesis of specifically deuterated adenosine A1 antagonist: BG9928. J Label Compd Radiopharm 50:219\u2013223","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR138","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1021\/acs.cgd.0c00107","volume":"20","author":"V Dubovoy","year":"2020","unstructured":"Dubovoy V, Desai P, Hao Z, Cheng C-y, Verma G, Wojtas L, Brinzari TV, Boyd JM, Ma S, Asefa T (2020) Synthesis, characterization, and antimicrobial investigation of a novel chlorhexidine cyclamate complex. Cryst Growth Des 20:4991\u20134999","journal-title":"Cryst Growth Des"},{"key":"515_CR139","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jlcr.1383","volume":"50","author":"M Moser","year":"2007","unstructured":"Moser M, Hudlicky T, Sadeghi S, Sternin E (2007) Synthesis of deuterium-labelled chlorhexidine. J Label Compd Radiopharm 50:671\u2013674","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR140","doi-asserted-by":"publisher","first-page":"13315","DOI":"10.1073\/pnas.0605805103","volume":"103","author":"BN Prasad","year":"2006","unstructured":"Prasad BN, Kumar V, Gururaj H, Parimalan R, Giridhar P, Ravishankar G (2006) Retracted: characterization of capsaicin synthase and identification of its gene (csy1) for pungency factor capsaicin in pepper (Capsicum sp.). Proc Natl Acad Sci USA 103:13315\u201313320","journal-title":"Proc Natl Acad Sci USA"},{"key":"515_CR141","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejphar.2013.10.053","volume":"720","author":"SK Sharma","year":"2013","unstructured":"Sharma SK, Vij AS, Sharma M (2013) Mechanisms and clinical uses of capsaicin. Eur J Pharmacol 720:55\u201362","journal-title":"Eur J Pharmacol"},{"key":"515_CR142","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jlcr.1678","volume":"52","author":"SW Kim","year":"2009","unstructured":"Kim SW, Park JH, Jung SJ, Choi TB, Hur MG, Yang SD, Yu KH (2009) Synthesis and elucidation of deuterated vanillylamine hydrochloride and capsaicin. J Label Compd Radiopharm 52:563\u2013565","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR143","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jaad.2005.10.061","volume":"54","author":"R Bissonnette","year":"2006","unstructured":"Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslet L, Huizinga R, Mayo P, Foster RT, Yatscoff RW, Maksymowych WP (2006) A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol 54:472\u2013478","journal-title":"J Am Acad Dermatol"},{"key":"515_CR144","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40265-021-01488-z","volume":"81","author":"Y-A Heo","year":"2021","unstructured":"Heo Y-A (2021) Voclosporin: first approval. Drugs 81:605\u2013610","journal-title":"Drugs"},{"key":"515_CR145","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0031-1289616","volume":"44","author":"J-H Maeng","year":"2012","unstructured":"Maeng J-H, Yang Z, Manning DD, Masih L, Cao Y, Pattamana KG, Bois F, Molino BF (2012) Organozirconium chemistry on cyclosporin: a novel process for the highly stereoselective synthesis of (E)-ISA247 (Voclosporin) and close analogues. Synthesis 44:63\u201368","journal-title":"Synthesis"},{"key":"515_CR146","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/jlcr.1392","volume":"50","author":"DP Richards","year":"2007","unstructured":"Richards DP, Sojo LE, Keller BO (2007) Quantitative analysis with modern bioanalytical mass spectrometry and stable isotope labeling. J Label Compd Radiopharm 50:1124\u20131136","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR147","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/jlcr.1657","volume":"52","author":"SJ Rozze","year":"2009","unstructured":"Rozze SJ, Fray MJ (2009) Unusual base-catalyzed exchange in the synthesis of deuterated PF-2413873 a. J Label Compd Radiopharm 52:435\u2013442","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR148","first-page":"431","volume":"17","author":"SJ Robins","year":"2006","unstructured":"Robins SJ, Bloomfield HE (2006) Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 17:431\u2013439","journal-title":"Curr Opin Lipidol"},{"key":"515_CR149","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1016\/j.bmcl.2007.05.066","volume":"17","author":"Y Yamazaki","year":"2007","unstructured":"Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K (2007) Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor \u03b1 agonists. Bioorg Med Chem Lett 17:4689\u20134693","journal-title":"Bioorg Med Chem Lett"},{"key":"515_CR150","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.bmc.2009.01.049","volume":"17","author":"Y Yamazaki","year":"2009","unstructured":"Yamazaki Y, Ogawa S-i, Shibuya K (2009) Synthesis of highly deuterium-labeled (R)-K-13675, PPAR \u03b1 agonist, for use as an internal standard for low-level quantification of drugs in plasma. Bioorg Med Chem 17:1911\u20131917","journal-title":"Bioorg Med Chem"},{"key":"515_CR151","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.3390\/molecules28155651","volume":"28","author":"R Munir","year":"2023","unstructured":"Munir R, Zahoor AF, Javed S, Parveen B, Mansha A, Irfan A, Khan SG, Irfan A, Kotwica-Mojzych K, Mojzych M (2023) Simmons-Smith cyclopropanation: a multifaceted synthetic protocol toward the synthesis of natural products and drugs: a review. Molecules 28:5651","journal-title":"Molecules"},{"key":"515_CR152","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3390\/molecules28062722","volume":"28","author":"A Mushtaq","year":"2023","unstructured":"Mushtaq A, Zahoor AF, Bilal M, Hussain SM, Irfan M, Akhtar R, Irfan A, Kotwica-Mojzych K, Mojzych M (2023) Sharpless asymmetric dihydroxylation: an impressive gadget for the synthesis of natural products: a review. Molecules 28:2722","journal-title":"Molecules"},{"key":"515_CR153","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.3390\/ijms21239279","volume":"21","author":"S Malaca","year":"2020","unstructured":"Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busard\u00f2 FP, Huestis MA (2020) Toxicology and analysis of psychoactive tryptamines. Int J Mol Sci 21:9279","journal-title":"Int J Mol Sci"},{"key":"515_CR154","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jlcr.1557","volume":"51","author":"SD Brandt","year":"2008","unstructured":"Brandt SD, Tirunarayanapuram SS, Freeman S, Dempster N, Barker SA, Daley PF, Cozzi NV, Martins CP (2008) Microwave-accelerated synthesis of psychoactive deuterated N, N-dialkylated-[\u03b1, \u03b1, \u03b2, \u03b2-d4]-tryptamines. J Label Compd Radiopharm 51:423\u2013429","journal-title":"J Label Compd Radiopharm"},{"key":"515_CR155","doi-asserted-by":"publisher","first-page":"8158","DOI":"10.1021\/bi00487a025","volume":"29","author":"SO Smith","year":"1990","unstructured":"Smith SO, Palings I, Miley ME, Courtin J, De Groot H, Lugtenburg J, Mathies RA, Griffin RG (1990) Solid-state NMR studies on the mechanism of the opsin shift in the visual pigment rhodopsin. Biochemistry 29:8158\u20138164","journal-title":"Biochemistry"},{"key":"515_CR156","doi-asserted-by":"publisher","first-page":"12819","DOI":"10.1021\/bi0491191","volume":"43","author":"GF Salgado","year":"2004","unstructured":"Salgado GF, Struts AV, Tanaka K, Fujioka N, Nakanishi K, Brown MF (2004) Deuterium NMR structure of retinal in the ground state of rhodopsin. Biochemistry 43:12819\u201312828","journal-title":"Biochemistry"},{"key":"515_CR157","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1246\/bcsj.80.2177","volume":"80","author":"K Tanaka","year":"2007","unstructured":"Tanaka K, Struts AV, Krane S, Fujioka N, Salgado GF, Mart\u00ednez-Mayorga K, Brown MF, Nakanishi K (2007) Synthesis of CD3-labeled 11-cis-retinals and application to solid-state deuterium NMR spectroscopy of rhodopsin. Bull Chem Soc Jpn 80:2177\u20132184","journal-title":"Bull Chem Soc Jpn"},{"key":"515_CR158","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-0348-8348-1_9","volume-title":"Glucocorticoids","author":"MB Feinstein","year":"2001","unstructured":"Feinstein MB, Schleimer RP (2001) Glucocorticoids. Springer, Berlin, pp 147\u2013158"},{"key":"515_CR159","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1043-2760(02)00566-0","volume":"13","author":"PM Stewart","year":"2002","unstructured":"Stewart PM, Tomlinson JW (2002) Cortisol, 11\u03b2-hydroxysteroid dehydrogenase type 1 and central obesity. Trends Endocrinol Metab 13:94\u201396","journal-title":"Trends Endocrinol Metab"},{"key":"515_CR160","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12020-009-9269-9","volume":"37","author":"C Campino","year":"2010","unstructured":"Campino C, Carvajal CA, Cornejo J, Mart\u00edn BS, Olivieri O, Guidi G, Faccini G, Pasini F, Sateler J, Baudrand R (2010) 11\u03b2-Hydroxysteroid dehydrogenase type-2 and type-1 (11\u03b2-HSD2 and 11\u03b2-HSD1) and 5\u03b2-reductase activities in the pathogenia of essential hypertension. Endocrine 37:106\u2013114","journal-title":"Endocrine"},{"key":"515_CR161","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.steroids.2005.04.006","volume":"70","author":"A Sulima","year":"2005","unstructured":"Sulima A, Prisinzano TE, Spande T, Deschamps JR, Whittaker N, Hochberg Z, Jacobson AE, Rice KC (2005) A concise method for the preparation of deuterium-labeled cortisone: synthesis of [6, 7\u20132H] cortisone. Steroids 70:763\u2013769","journal-title":"Steroids"},{"key":"515_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetlet.2019.151037","volume":"60","author":"Y Taniguchi","year":"2019","unstructured":"Taniguchi Y, Cao X, Sasaki S (2019) Synthesis of the deuterated thymidine-d9 and deuterated oligonucleotides. Tetrahedron Lett 60:151037","journal-title":"Tetrahedron Lett"},{"key":"515_CR163","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/15257770.2019.1669170","volume":"39","author":"N Miyamoto","year":"2020","unstructured":"Miyamoto N, Ohno H, Kitamura Y, Park K, Sawama Y, Sajiki H, Kitade Y (2020) Practical and reliable synthesis of 2\u2032, 3\u2032, 5\u2032, 5\u2033-tetradeuterated uridine derivatives. Nucleosides Nucleotides Nucleic Acids 39:236\u2013244","journal-title":"Nucleosides Nucleotides Nucleic Acids"}],"container-title":["Topics in Current Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41061-025-00515-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41061-025-00515-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41061-025-00515-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T07:02:38Z","timestamp":1757487758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41061-025-00515-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":163,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1007\/s41061-025-00515-x","relation":{},"ISSN":["2364-8961"],"issn-type":[{"value":"2364-8961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"31"}}